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Abstract
Background: Circulating DNA (ctDNA) is acknowledged as a potential diagnostic tool for various cancers including
colorectal cancer, especially when considering the detection of mutations. Certainly due to lack of normalization of the
experimental conditions, previous reports present many discrepancies and contradictory data on the analysis of the
concentration of total ctDNA and on the proportion of tumour-derived ctDNA fragments.
Methodology: In order to rigorously analyse ctDNA, we thoroughly investigated ctDNA size distribution. We used a highly
specific Q-PCR assay and athymic nude mice xenografted with SW620 or HT29 human colon cancer cells, and we correlated
our results by examining plasma from metastatic CRC patients.
Conclusion/Significance: Fragmentation and concentration of tumour-derived ctDNA is positively correlated with tumour
weight. CtDNA quantification by Q-PCR depends on the amplified target length and is optimal for 60–100 bp fragments. Q-
PCR analysis of plasma samples from xenografted mice and cancer patients showed that tumour-derived ctDNA exhibits a
specific amount profile based on ctDNA size and significant higher ctDNA fragmentation. Metastatic colorectal patients
(n = 12) showed nearly 5-fold higher mean ctDNA fragmentation than healthy individuals (n = 16).
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Introduction
Recent advances in the understanding of the molecular
mechanisms of cancer enlarge the scope of diagnostic strategies in
oncology [1]. Many genetic alterations involved in tumourigenesis
are now positioned within a time sequence [2]. Moreover it is fully
acknowledged that tumours release cell-free nucleic acids in
biological fluids, especially blood [3]. Therefore, the detection of
the genetic alterations associated with tumour development in
circulating DNA (ctDNA) appears to be a particularly attractive
approach as a non-invasive, diagnostic or theranostic test for
cancers [4]. Previously, ctDNA was used as biomarker in two ways:
first by measuring its concentration and second by studying its
nucleotidic sequence [4,5]. Moreover, ctDNA levels in plasma have
been shown (i) to be significantly higher in CRC patients than in
healthy individuals [6]; (ii) to decrease progressively in the follow-up
period in tumour-free patients; and (iii) to increase in patients with
cancer recurrence or metastasis [5,7,8]. Many studies have been
focusing on the identification of abnormal forms of DNA in plasma
or serum; however, the reported results are so far contradictory,
although very high rates of cancer detection have been obtained in
such a way. These reports, although promising, have led to many
questions about the reliability of using abnormal ctDNA as cancer
biomarker [9,10]. Particularly, it is imperative to develop
technologies that can detect the number of mutant DNA molecules
and the specific mutation(s) in the same sample. For this it is
necessary to improve the sensitivity and specificity of ctDNA
analysis. In addition, in order to be able to compare results across
samples and studies, it is necessary to have detailed information
about the amount and the size distribution of ctDNA fragments and
to compare the data obtained for neoplastic and non-neoplastic cell
ctDNA. Necrosis, which is associated with tumour development, as
well as apoptosis and phagocytosis, which are associated with
defence mechanisms, lead to destruction of tumour cells and also of
the adjacent, non-tumour tissues [11,12,13,14], and to DNA
fragmentation as an hallmark of apoptosis. However, fragmentation
of cell-free DNA is higher following apoptosis than following
necrosis or phagocytosis [13]. Specifically, ctDNA fragments longer
than 10,000 bp are likely to originate from necrotic cells, whereas
DNA fragments shorter than 1000 bp, particularly of 180 bp or
multiples of this size, are reminiscent of the oligonucleosomal DNA
ladder observed in apoptotic cells [15]. Thus, a detailed analysis of
the size of the ctDNA fragments could allow discerning the source of
circulating nucleic acid in cancer patients. To this aim we developed
a highly specific Q-PCR assay that has already allowed us to
unequivocally identify tumour and non-tumour derived ctDNA
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released during cancer progression in an animal model (athymic
nude mice xenografted with human colon cancer cells) [16]. Here,
we have used this assay to evaluate the amount and size distribution
of non-tumour and tumour-derived ctDNA fragments. We then
have applied the same system to quantify ctDNA fragments and
their size distribution in plasma samples from healthy individuals
and patients with metastatic colorectal cancer (CRC). Our data
revealed that analysis of ctDNA fragmentation provides valuable
information relative to cancer diagnosis.
Materials and Methods
1. Cell lines
Human HCT116-s [17], SW620 (ATCC: CCL-227) and HT29
(ATCC: HTB-38) cells and mouse MC38 [18] colon carcinoma
cell lines were maintained in RPMI + 10% fetal bovine serum.
2. Xenograft model
Female athymic nude mice (6–8 wk/old) were purchased from
Harlan (Gannat, France) and maintained in a specific pathogen-
free facility (study approval Nu B-34-172-27; Institut de Recherche
en Cance´rologie de Montpellier-CRLC Val d’Aurelle-Paul
Lamarque, Montpellier, France). Mice were xenografted subcuta-
neously with 26106 cancer cells. Mice were euthanized with CO2
at different time points post-graft according to the tumour weight
desired. Peripheral blood was drawn into EDTA pre-coated tubes
and was used for plasma preparation within one hour. All
experiments complied with the current national and institutional
regulations and ethical guidelines and were performed by an
accredited person (Dr. B. ROBERT, Nu34-156).
3. Human blood samples
Blood samples from patients with metastatic colorectal cancer
(CRC) (n=12) and from selected human healthy individuals (human
healthy plasma, HHP, n=16) were collected in EDTA tubes. The
overall process from blood collection to plasma preparation did not
exceed 3 hours and plasma was stored at280Cu. Written, informed
consent was obtained from all participants prior to the onset of the
study. Protocols for the use of blood of healthy volunteers used in this
study were approved by the ‘‘Etablissement Franc¸ais du Sang’’ (EFS)
Ethics Committee (EFS-PM agreement: 21/PVNT/MTP/
CNR14/2010-0029). According to the Code de Sante´ Publique
Article L1131-1 and next, no specific ethical approval is required for
this type of study. Each CRC and HHP sample was numbered
(CRCn and HHPn) and corresponded to the plasma of a single
subject with the exception of HHP3, which was a pool of 6 different
plasma samples. TNM classification of CRC 1–4 patients corre-
spond to T4N3M1, T3N2M1, T4N1M1 and TxN2M1, respective-
ly. All metastatic CRC patients did not received chemotherapy at
least one month before blood collection.
4. Plasma preparation
Mouse and human blood was collected in 4 ml Venosafe K2E
tubes (Terumo) and centrifuged at 1200 g at 4uC in a Heraeus
Multifuge LR centrifuge with a CR 4j rotor for 10 minutes.
Supernatants were isolated in sterile 1.5 ml Eppendorf tubes and
centrifuged at 16 000 g at 4uC for 10 min. Then, supernatants
were either immediately handled for DNA extraction or stored at
280uC. No significant difference was found in Q-PCR assays
when comparing freshly isolated or stored plasma.
5. DNA extraction
ctDNA was isolated from 200 ml plasma with the QIAmp DNA
Mini Blood kit (Qiagen, CA) according to the ‘‘Blood and body
fluid protocol’’ in an elution volume of 60 ml. DNA samples were
kept at 220uC until use. No significant difference was found in the
results of the Q-PCR assays in which freshly extracted or stored
DNA was used.
6. Oligonucleotides
The oligonucleotide primers used in this work are described in
Table S1. Primers were designed and selected according to the
previously described methods [16].
7. CtDNA quantification by Q-PCR
The Q-PCR method and ctDNA analysis were previously
described in detail [16]. Methodology and data description were
carried out according to the MIQE guidelines [19]. Q-PCR
amplifications were carried out in a reaction volume of 25 ml on a
Chromo4 instrument using the MJ Opticon Monitor 3 software
(Bio-Rad). Each PCR reaction mixture was composed of 12.5 ml
PCR mix (Bio-Rad Super mix SYBR Green); 2.5 ml of each
amplification primer (0.3 pmol/ml); 2.5 ml PCR-analyzed water
and 5 ml DNA extract. Thermal cycling was organised in 3
repeated steps: a first denaturation step of 3 min at 95uC, followed
by 40 repeated cycles of 95uC for 10 sec and 60uC for 30 sec.
Melting curves were obtained by increasing the temperature from
55uC to 90uC with a plate reading every 0.2uC., Serial dilutions of
genomic DNA from human placenta cells were used as calibrators
for quantification, their concentration being assessed with a
Nanodrop spectrophotometer. Each sample was analyzed in
duplicate and each assay repeated at least once. The ctDNA
concentrations obtained with each primer set were normalized to
the precise concentration of a genomic DNA sample amplified
using the same primer set. The coefficient of variation due to
ctDNA extraction and of concentration value was calculated as
4% and 19% respectively (n = 12). The ctDNA amount was
arbitrarily estimated for the 60–100, 100–150, 150–400 and
.400 bp fragment size ranges. ctDNA amount was determined
for 1 ml and expressed as ng. The estimated amount of ctDNA in
each range of ctDNA size was calculated by subtracting the
amount obtained with the larger amplicon from the amount
obtained with the shorter amplicon (100 bp minus 60 bp, 150 bp
minus 100 bp, 400 bp minus 150 bp). The fraction corresponding
to ctDNA fragment higher than 400 bp corresponds to the
amount obtained when targeting sequence of 382 bp (mouse) or
409 bp (human).
8. Estimation of ctDNA fragmentation
CtDNA fragmentation was assessed by calculating an index we
termed DNA Integrity Index (DII). DII was calculated as the ratio
of larger/shorter fragment concentrations. DII is therefore
theoretically 1 if the template DNA is not truncated and ,1 if it
is truncated into fragments smaller than the template. Conven-
tionally, long and short fragments were longer or shorter than
180 bp (i.e., the mononucleosome average size). To note, DII did
not significantly vary when Q-PCR analysis was either carried out
2 hours following blood sampling or after plasma freezing,
provided that no blood degradation was observed after 4 hours
in EDTA (ethylenediaminetetraacetic acid) tubes at room
temperature (data not shown). In addition, samples were handled
in the same way in the same experiments.
9. Q-PCR targeted sequences
Targeted sequences are located in two genes: KRAS and ACTB
(Table S1). Evaluation of ctDNA fragmentation was performed
using an original double integrated PCR system that targets
Fragmentation of Tumour-Derived Circulating DNA
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human ACTB sequences [16] or intron 2 of the mouse or human
KRAS gene in which the reverse primer was the same for the short
and the long fragment (Fig. 1, A and B).
The amount profile of ctDNA fragments of different size was
assessed using an integrated PCR system that target intronic
sequences of mouse or human origin within the same region. For
the human wild type specific primer set the designed sizes of
amplification were 60 bp, 73 bp, 101 bp, 145 bp, 185 bp, 249 bp,
300 bp, 357 bp and 409 bp (the reverse primer was the same for
each amplification system). These primers targeted intron 2 of
human KRAS (Fig. 1, C). For the mouse wild type specific primer
set the designed sizes of amplification were 63 bp, 95 bp, 150 bp,
196 bp, 256 bp, 284 bp, 354 bp and 382 bp (the reverse primer
was the same for each amplification system). These primers
targeted intron 7 of mouse KRAS (Fig. 1, D). The median of the
non-specific amplification of the mouse and human KRAS primer
sets, assessed by determining the concentration profile of aliquots
of human placental DNA and of MC38 DNA, was 7% and 9%,
respectively.
10. Statistical analysis
Data were expressed as mean 6 SD. The Student’s t-test was
used for comparison of means. A probability of less than 0.05 was
considered to be statistically significant; *p # 0.05, **p # 0.01,
***p # 0.001.
Results
1. ctDNA fragmentation increases with tumour size and
tumour ctDNA concentration
Nude athymic mice xenografted with HT29 cells were sacrificed
at different time points, tumours were weighted and ctDNA
concentration in plasma samples determined using the HuACTB
133 primer pair that targets a 133 bp sequence in the human
ACTB gene (Fig. 2, A). The concentration of ctDNA increased
slightly (from 0.23 to 4.8 ng/ml) in samples from mice bearing
small tumours (,500 mg), but then rapidly augmented up to
19 ng/ml in samples from mice with bigger tumours (.500 mg).
Then, the corresponding DII was calculated using the ctDNA
concentrations obtained with this primer pair and the values
obtained with the HuACTB 290 primer set that amplifies a longer
amplicon (290 bp). DII sharply decreased (from 0.44 to 0.1) in
samples from mice with tumours up to 400 mg and then remained
constant at approximately 0.05, notwithstanding the steadily
increase in tumour weight.
2. ctDNA quantification by Q-PCR highly varies according
to the amplicon length
Since the previous results indicate that ctDNA fragmentation
increases with tumour progression, we then tested using our PCR
system whether the evaluation of ctDNA concentration could be
Figure 1. Primer designs used in the study. Primer targeting an ACTB region for quantifying ctDNA and determining ctDNA fragmentation from
HT29 xenografted mice (A). Primer targeting a human KRAS region for studying the effect of the target sequence size on ctDNA concentration and
fragmentation in plasma from SW620 xenografted mice (B). Primer design for studying the size distribution profile of ctDNA fragments in plasma
from SW620 xenografted mice and human individuals by targeting human (C) and mouse (D) KRAS region.
doi:10.1371/journal.pone.0023418.g001
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influenced by the amplicon length. To this aim, the concentration
of tumour ctDNA in plasma samples of mice xenografted with
SW620 cells was quantified using three human KRAS primer pairs
that amplify sequences of 73 bp, 145 bp and 300 bp (Fig. 2, B)
and with KRAS primers targeting mouse and human KRAS (214
and 189 bp, Figure S1). With the KRAS 300 primers (300 bp
amplicon) ctDNA was not detected in plasma samples from the
mice with the smallest tumours (,174 mg), but then, in samples
from mice with tumours heavier than 174 mg, the ctDNA
concentration decreased progressively with the increase of tumour
weight. On the other hand, the ctDNA concentrations obtained
using the KRAS 145 primer set seemed to slightly increase with
tumour size. Conversely, with the KRAS 73 primers the ctDNA
concentration highly increased in parallel with tumour weight.
Data obtained by detecting 145 and 73 bp KRAS amplicon
confirmed the increase of ctDNA concentration with tumour
weight observed in HT29 cells by detecting 133 bp ACTB
amplicon (Fig. 2, A). These results indicate that the quantification
Figure 2. Evolution of tumour-derived ctDNA fragmentation and concentration relative to tumour weight. (A): Athymic nude mice
were xenografted with HT29 cells and sacrificed at various time points and thus with tumours of increasing weight (137, 189, 310, 380, 400, 1019,
1080 mg from Mo1 to Mo7, respectively). CtDNA concentration (ng/ml plasma, left y axis) (dashed line) was assessed by Q-PCR using a primer set that
amplifies a 133 bp sequence from human ACTB (Fig. 1A). Tumour-derived ctDNA fragmentation (full line) was estimated by calculating the DII (right y
axis). Here, the DII corresponds to the ratio of the concentration found when targeting a 290 bp sequence of the human ACTB gene to the
concentration found when targeting a 133 bp sequence located within the former 290 bp region (Fig. 1A). (B): Tumour ctDNA was quantified by Q-
PCR with human KRAS 73 (empty bars), KRAS 145 (hatched bars) and KRAS 300 (full bars) primer sets (Fig. 1B) in plasma samples from SW620
xenografted mice. Mo8, Mo9 and Mo10 correspond to three non-xenografted nude mice. CtDNA fragmentation was estimated by calculating the
300/145 and 300/73 DII. DII was calculated as the ratio of the ctDNA concentrations obtained from the amplification of a short 73 bp, a medium
145 bp and a long 300 bp target sequence from the human KRAS gene (Fig. 1B). Bars represent ctDNA concentration expressed as ng/ml of plasma
(left y axis) and curve represents tumour weight (mg, right y axis). Data represent the mean values of the ctDNA concentrations obtained in
duplicates. NC, not calculated. No ctDNA was detected with the KRAS 300 bp primers in Mo11 and Mo12 plasmas.
doi:10.1371/journal.pone.0023418.g002
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of ctDNA concentration is strongly influenced by the choice of the
amplicon length. For instance, the ctDNA concentration in mouse
#16 determined with the KRAS 73 primers was 5.3- and 40.5-fold
higher than the concentrations obtained with the KRAS 145 and
KRAS 300 primer pairs, respectively. The DII was then calculated
(Fig. 2, B). Although both KRAS 300/145 and KRAS 300/73 DII
decreased with tumour progression (13- and 30-fold decrease,
respectively), KRAS 300/145 DII remained more elevated than
300/73 DII (for instance the mouse #16 DII was 0.13 for the
KRAS 300/145 ratio and 0.02 for the KRAS 300/73 ratio).
3. Tumour-derived ctDNA fragments exhibit a specific
size distribution in xenografted mice
The previous results indicate that quantification of tumour
ctDNA is influenced by the amplicon size. We thus asked whether
the size distribution profiles of neoplastic and non-neoplastic
ctDNA fragments were different. In order to reduce as much as
possible the effect of tumour size, ctDNA was quantified by
calculating the mean concentration values in three pools of plasma
from three mice with tumours weighing between 300 and 550 mg
(Fig. 3). The concentration profile of the different non-tumoral
ctDNA fragments in these pooled samples, obtained using mouse
KRAS primers that amplify fragments of increasing length up to
382 bp, was similar to that of control, non-xenografted mice
(Fig. 3A and B). With human KRAS primers that amplify tumour-
derived ctDNA fragments of increasing length up to 409 bp, the
highest ctDNA concentrations were obtained for amplicons of
length ,100 bp and were much higher than the values obtained
for mouse (non-tumoral and control) ctDNA. Conversely, when
detecting amplicons of size ranging from 100 to 150 bp
comparable levels of non-tumour, tumour-derived and control
ctDNA were obtained, and for amplicons .185 bp lower
concentrations of tumoral than non-tumoral ctDNA were found
(p = 0.047 and 0.007 for the 185 bp and 250 bp amplicons,
Figure 3. CtDNA fragment size profiles determined by Q-PCR for amplicons of different length in xenografted mice. Evaluation of
tumour and non-tumour ctDNA concentration in plasma samples from mice xenografted with SW620 cells and of control ctDNA in non-xenografted
nude mice was determined using a multi-integrated Q-PCR system for detecting amplicons of increasing length in intron 2 of human wild type KRAS
(Fig. 1) or in intron 7 of mouse wild type KRAS (Fig. 1). Tumour ctDNA, non-tumour ctDNA and control ctDNA concentrations are expressed as ng/ml
of plasma (A) or as % of the highest value of each concentration set (B). Each point represents the mean of three pools of plasma from three mice
with 300–550 mg tumours. The relative percentage of tumour and non-tumour ctDNA from xenografted mice for each amplicon length is presented
in (C): Tumour (black bars) and non-tumour (hatched bars) ctDNA mean concentrations are expressed as ng/ml of plasma; the bar height is the sum
of tumour and non-tumour ctDNA concentrations (estimated as the total ctDNA concentration). For clarity human and mouse amplified targeted
sequences of close size were grouped together: 60 (60 and 63), 100 (101 and 95), 150 (145 and 150), 200 (185 and 196), 250 (249 and 256), 350 (354
and 357) and 400 (409 and 382) bp. Fractional fragment size distribution of ctDNA amount from tumour and non-tumour ctDNA in xenografted mice
and control ctDNA in non-xenografted mice (D). The ctDNA amount was arbitrarily estimated for the 60–100, 100–150, 150–400 and .400 bp
fragment size ranges. The estimated amount of ctDNA (ng) in one ml of plasma in each range of ctDNA size was calculated as described in Materials
and Methods section.
doi:10.1371/journal.pone.0023418.g003
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respectively). These results indicate that 1) ctDNA fragments
smaller than 150 bp are predominantly detected in tumour
ctDNA extract; 2) the proportion of ctDNA of tumour origin is
inversely correlated with the amplicon size (from less than 20% of
the total detectable ctDNA for the 400 bp amplicon to 85% for the
60 bp amplicon) (Fig. 3C). Finally, ctDNA amount upon
arbitrarily selected size ranges (Fig. 3D) highlights that tumour-
derived ctDNA amount could be easily discriminated versus non
tumour and control ctDNA when targeting sequence ,100 bp (65
vs 2–5 ng) and when targeting sequence .400 bp (2 vs 9–10 ng).
4. The specific size distribution profile of tumour ctDNA
fragments appears to be relevant also in CRC patients
The same human KRAS primer sets that amplify DNA
fragments of different size (Fig. 1, C) was used to study the
ctDNA size distribution in plasma samples from healthy
individuals (HPP) and four metastatic CRC patients who were
not under treatment (CRC1 to CRC4) (Fig. 4). Overall higher
ctDNA concentrations were detected in CRC plasma samples
than in HHP samples (Table 1). For instance, the plasma DNA
concentrations determined with the primers that amplify the 60 bp
amplicon were 8078, 2134, 618 and 402 ng/ml for CRC1, CRC2,
CRC3 and CRC4 and 24.8, 11.2 and 18.4 ng/ml in HHP1,
HHP2 and HHP3, respectively. Moreover, whereas among CRC
patients ctDNA levels were very different, in healthy individuals
they did not vary much as the mean +/2 SD was 18.1+/26.8. To
note, the value of HHP3, which is a pool of plasmas from 7
different healthy donors, was similar to that of the individual
HHP1 and HHP2 samples. The mean ctDNA amount in human
healthy individuals was found maximal at 60–100 bp (49%) range
while being very low at 150–400 bp range (1%). Except for the
.400 bp range HHP ctDNA amount was much lower (of several
order) than that of CRC ctDNA amount observed when fragments
are ,400 bp. In particular, CRC ctDNA amount observed within
150–400 bp rise to 178–1520 ng whereas HHP amount was very
poor (,1 ng). Conversely, the relative CRC ctDNA amount
detected for fragment .400 bp appears very low (1–5%),
suggesting that the relative determination of ctDNA amount
within a fragment size range might distinguish healthy vs CRC
plasmas. In this regard, the 300/60 DII calculated from the
concentration values obtained when detecting target sequence of
300 and 60 bp, was 0.45 for the HHP and 0.055 for the CRC
samples (Table 1).
5. Comparison of the fractional size distribution of ctDNA
in CRC patients and xenografted animals
Figure 5 shows the relative ctDNA amount from plasmas of
human (Fig. 5A) and mouse (Fig. 5B) origin. The percentage of
60–150 bp ctDNA was rather similar in HHP and CRC samples
despite the higher proportion of tumour ctDNA observed for the
60–100 bp range. Decreased but significant ctDNA amounts for
the 150–400 range were detected in CRC samples, but not in
HHP samples. Conversely, the amount of .400 bp ctDNA in
HHP samples (approximately 35%) was 17-fold higher than in
CRC samples (2%).
A similar method of evaluation of the ctDNA amount was
employed for the data (Fig. 3) obtained in xenografted mice (Fig. 5,
B). The amount of mouse ctDNA relative to fragment size range was
comparable in non-xenografted (control) and xenografted mice
(non-tumoral) and its distribution profile was similar to the one
observed in healthy controls (Fig. 5, A) with a noticeable very low
percentage in the 150–400 size range and a significant higher
proportion of .400 bp ctDNA (39% and 52% for control and
non-tumoral mouse ctDNA). Conversely, the percentage of tumour-
derived ctDNA in the 60–100 bp range was very high (71%) and
decreased sharply to 2% for fragments .400 bp. The fractional
fragment size distribution of tumour-derived ctDNA from xeno-
grafted mice and CRC patients was comparable (Fig. 5A and B).
6. Comparison of the DII in healthy and CRC patients and
in xenografted animals
The ratio between the mean HHP DII and the CRC DII was
close to 1 for the 60/60 DII and 1.5 for 150/60 DII bp, but
sharply increased to 4–19 for the 300/60 DII (Fig. 6). This
indicates that the main differences in ctDNA fragmentation
between healthy and cancer patients are observed for long
Figure 4. ctDNA size profile upon amplicon length. Comparison
of ctDNA size profile upon amplicon length in healthy individuals (HHP)
and CRC patients (A). CtDNA amount was calculated as described in
Material and Methods section. The corresponding concentration values
for each CRC and HHP plasma sample are presented in Table 1. HHP is
the mean from plasmas of two healthy individuals (HHP1 and HHP2)
and of a pool of 7 healthy individuals (HHP3). The estimated amount of
ctDNA in each range of ctDNA size was calculated as described in
Materials and Methods section. HHP and CRC ctDNA concentration are
expressed as % of total ctDNA value of each profile (B). CtDNA
concentration was determined using a multi-integrated Q-PCR system
for detecting amplicons of increasing length in intron 2 of human wild
type KRAS (Fig. 1) as performed in Fig. 3.
doi:10.1371/journal.pone.0023418.g004
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amplicons (145–409 and .409 bp). DII from mouse plasmas
between the ctDNA concentration of each amplicon .60 bp and
that of the 60 bp amplicon was calculated (Table S2). The DII
ratios can clearly discriminate tumour ctDNA from non-tumour
ctDNA detected in xenografted or non-xenografted mice. The
profile of the DII ratios of non-xenografted and xenografted mice
remarkably appears similar to those calculated from human
healthy individuals and CRC patients. DII appears to similarly
discriminate tumour-derived ctDNA from non tumour-derived or
control ctDNA. Results strongly confirmed that 300/60 DII seems
optimal for discriminating healthy to CRC subjects (Fig. 6). DII
mean value of HHP (n= 16) is significatively different from DII
mean value of CRC (n= 12) (mean, 0.565 and 0.122, respectively;
p,0.001) (Fig. 7). A similar difference was observed in an animal
model where mean DII is 0.447 for healthy plasma ctDNA (n= 9),
0.645 for non tumour-derived ctDNA (n= 9) and 0.027 for
tumour derived ctDNA (n= 9). The DII values did not seem to be
influenced by the genome localization of the amplicons, since
comparable results were obtained with amplicons localized in
intron 2 and exon 2 of KRAS and in exon 15 of BRAF (0.036+/
20.006, data not shown).
Discussion
Here we demonstrate that the length of the amplified fragment
dramatically influences the measurement of the ctDNA concen-
tration by Q-PCR. Specifically, a significant higher proportion of
tumour ctDNA is detected by primers that target amplicons
,100 bp, suggesting that the detection of amplicons ,100 bp is
more relevant for tumour ctDNA.
Since it was previously established that the shortest ctDNA should
theoretically be .180 bp (size of a nucleosome) and since Q-PCR
efficiency is conventionally (with genomic DNA) optimal when
amplifying sequence of 150–300 bp, most of the previous works
relied on the detection of amplicons of about 150 bp when
analyzing ctDNA. While Q-PCR assay was often used for ctDNA
study, only a couple of reports described the use of primers that
amplify segments ,100 bp and this choice was based solely on
technical aspects linked to primer design and/or to the targeted
gene region, but never on the assumption that a higher proportion
of ,100 bp ctDNA could be present in a specific physiological
condition or pathology. Here, we demonstrate, for the first time, the
presence of a higher proportion of ctDNA fragments,100 bp that
is directly correlated with the increase of ctDNA concentration,
particularly in samples from cancer patients. Thus, contrary to the
analysis of genomic DNA in which the concentration of quantified
DNA is directly proportional to the number of amplified copies, this
proportionality varies upon target sequence length in the case of
ctDNA from CRC patients. Moreover, the targeting of sequences of
150 to 250 bp (the length commonly chosen for amplification)
generates a significant bias by not taking into account up to 80% of
the ctDNA amount. Thus, the size profile of ctDNA, as determined
by amplifying targets of increasing length, reveals that the optimal
detection is obtained with amplicons ,100 bp and that a much
higher proportion of ctDNA of size ranging from 150 to 400 bp is
present in non-tumour ctDNA than in tumour ctDNA. The choice
of the size of the amplified DNA region consequently appears
critical. Moreover 98% of human CRC tumour ctDNA fragments
were ,409 bp.
Table 1. Total ctDNA concentration (ng/ml plasma) and DII in plasma samples from metastatic CRC patients (CRC1-4) and healthy
individuals (HHP1-3).
Samples Amplicons sizes (bp)
60 73 101 145 185 249 300 357 409
CRC 1 8077.8 6004.8 2395.5 1526.2 815.2 275.9 179.3 162.6 6.8
CRC 2 2133.9 2326.0 1016.5 596.2 409.3 267.2 175.1 105.1 123.9
CRC 3 618.1 591.5 289.9 187.7 93.2 46.1 37.5 20.3 9.9
CRC 4 402.2 286.3 179.0 77.4 81.3 135.3 62.9 28.1 34.1
HHP 1 24.8 16.5 9.8 5.9 7.0 6.0 3.6 2.4 3.0
HHP 2 11.2 12.8 7.6 6.1 6.4 6.8 8.0 5.2 7.4
HHP 3 18.4 17.3 11.6 6.4 5.2 9.8 9.0 4.4 4.7
Samples Integrity index
60/60 73/60 101/60 145/60 185/60 249/60 300/60 357/60 409/60
CRC 1 1.000 0.743 0.297 0.189 0.101 0.034 0.022 0.020 0.001
CRC 2 1.000 1.090 0.476 0.279 0.192 0.125 0.082 0.049 0.058
CRC 3 1.000 0.957 0.469 0.304 0.151 0.075 0.061 0.033 0.016
CRC 4 1.000 0.712 0.445 0.192 0.202 0.336 0.156 0.070 0.085
mean CRC 1.000 0.876 0.422 0.241 0.161 0.143 0.080 0.043 0.040
HHP 1 1.000 0.664 0.394 0.239 0.284 0.244 0.147 0.098 0.123
HHP 2 1.000 1.145 0.680 0.547 0.571 0.607 0.712 0.463 0.659
HHP 3 1.000 0.941 0.628 0.348 0.282 0.531 0.490 0.237 0.257
mean HHP 1.000 0.916 0.567 0.378 0.379 0.461 0.450 0.266 0.346
HHP/CRC 1.000 1.047 1.345 1.568 2.348 3.232 5.597 6.180 8.673
DII was evaluated by calculating the ratio between the concentration of each amplicon and that of the 60 bp amplicon. HHP/CRC is the ratio between the mean HHP DII
and the mean CRC DII.
doi:10.1371/journal.pone.0023418.t001
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Amplification of fragments of increasing size within the same
DNA region showed that non-tumoral ctDNA is less fragmented
than tumour ctDNA. In addition, the study revealed that tumour
ctDNA fragments have a distinct size profile in comparison to non-
tumoral ctDNA and ctDNA from non-xenografted mice. Frag-
ment size profile of non-tumoral, tumoral and control ctDNA are
similar in the animal model and in the clinical samples.
Specifically, our results suggest that the concentration level and
the size distribution profile of ctDNA fragments can be used to
discriminate between healthy and cancer patients. Particularly,
three ctDNA size groups (,100, 150–400 and .400 bp) might be
relevant for such discrimination; exhibiting a higher, much higher
and much lower ctDNA amount in cancer patients as compared
with healthy individuals, respectively. Thus, the specific analysis of
tumour ctDNA can be performed by using a DII calculated from
the concentrations of ctDNA of size ,100 bp and between 145–
409 bp and appears to be optimal when using the 300/60 DII in
both xenografted mice and untreated CRC patients. The
determination of DII significatively discriminates between HHP
and CRC plasmas indicating a higher fragmentation of the
corresponding ctDNA. Higher number of subjects is needed to
confirm this observation. Ellinger et al determined an integrity
index by targeting 124 bp and 271 bp sequences in plasma of
prostate [20] and testicular cancer patients [21] and suggested that
it witnesses the level of apoptosis among other mechanisms which
may release DNA from tumour cells to the circulation. In addition,
we think that DII could be very informative in regards to the
ctDNA fragment size profile and thus to the observation of the
tumour origin.
As a consequence the choice of target length is crucial when
determining the DII. This could explain the contradictory results
reported by the few previous studies on the clinical use of the
integrity index to follow cancer progression that did not allow
drawing general conclusions (i.e., estimation of ctDNA fragmen-
tation was found lower [22,23] equivalent [24,25] or higher
[13,21,26,27] than in controls). As stated by Jung et al [28] those
discrepancies might be related to pre-analytical and analytical
factors as well as possible bias in the selection of the study groups.
We suggest that they may be explained at least partially by the
possibility that a large proportion of tumour ctDNA is ,100 bp,
an option which has never been taken into account. In addition, it
is conceivable that our observation might be restricted to the
clinical status of the patients whose blood was here examined
(stage III mCRC patients not undergoing chemotherapy). Effect of
chemotherapy and influence of CRC stage on ctDNA analysis is
under investigation in our laboratory.
Our results on the tumour ctDNA size profile disagree with
many earlier reports. Most of these works described that ctDNA
Figure 5. Comparison of the fractional fragment size distribu-
tion of ctDNA from clinical samples and from the animal
model. CRC and healthy patients (A) and tumour and non-tumour
ctDNA in xenografted mice and control ctDNA in non-xenografted mice
(B). The estimated amount of each ctDNA fraction was expressed as the
percentage to the total ctDNA amount estimated as the sum of the
ctDNA amount of the four size fractions. Data were calculated from the
experiments presented in Table 1, Fig. 3 (mouse plasma samples) and
Fig. 4 (human plasma samples).
doi:10.1371/journal.pone.0023418.g005
Figure 6. Discrimination between healthy and CRC subjects by
comparing DII values. DII ratio between HHP and CRC patients (A)
and between control non-xenografted and SW620 xenografted mouse
plasma (B) were determined from DII values represented in Table 1 and
S2, respectively. DII of plasma from each CRC patient was compared
with the mean of healthy individuals (HHP, n = 9). Mouse DII ratios are
determined from the mean of 3 pools from 3 mice (n = 9). The DII was
estimated by the ratio of the concentration of amplicons of increasing
size and the concentration to the 60 bp amplicons.
doi:10.1371/journal.pone.0023418.g006
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consisted of fragments of approximatively 100 to 500 bp [29]. To
our knowledge, tumour-derived ctDNA lower than 80 bp was
previously never examined and quantified on the basis of their
higher proportion in ctDNA total population. Precise ctDNA size
profiling was reported only in a few works. Liu et al [30], by using
microfluidic single molecule spectroscopy, found a size profile for
ctDNA fragments .100 bp from stage I and IV lung cancer
patient sera that is quite similar to our results. However, they
concluded that the greatest discriminatory power occurred at a
threshold of 800 bp; no comparison was made with non-neoplastic
ctDNA. The authors never focused on ctDNA of size lower than
320 bp, arguing that below 320bp the two curves are similar. D.
Lo’s team [23] analyzed the size distributions of maternal and fetal
DNA in maternal plasma by using a Q-PCR assay with primer sets
that amplify sequences from 105 to 798 bp. They suggested that
‘‘most of the ctDNA molecules were in the range of 145–201 bp’’
(which is approximately the nucleosome size). None of the
previous reports did examine or discuss the possibility of ctDNA
of size lower than 105 bp [23,24,26,29,30].
Vogelstein’s group reported that 1350 to 230 000 ctDNA
fragments/ml were found in CRC patients’ plasma samples in
comparison to the 1150 to 8280 fragments/ml in disease-free
patients [9], confirming the partial overlap between ctDNA level
in healthy and CRC individuals described also in other studies
[3,4,5,28]. In our study, the fragment number in healthy controls
was comparable (2539+/2952 ctDNA fragments/ml, n= 9).
Conversely, the ctDNA amount in CRC plasma samples
(1,130,920; 298,760; 86,520 and 56,280 fragments/ml as
determined by detecting a 60 bp amplicon) was much higher
than in control samples, irrespective of the amplicon length. There
is a 25-fold disparity when comparing the highest HHP ctDNA
value to the lowest CRC ctDNA concentration in our study. This
might certainly be due to the Q-PCR analysis that targets a 60 bp
sequence and/or the clinical state of the CRC patients group at
blood sample time we examined (untreated mCRC). This
specificity level may be as well worth further study with a much
higher number of clinical samples.
In conclusion, higher and more accurate ctDNA quantification
is now made possible enabling a novel examination of ctDNA as
cancer biomarker. Size profiling or DII determination could
appear as additional potential biomarker, especially during cancer
patient monitoring. However, more work has to be done
concerning the number of clinical samples and the robustness of
those observations to strengthen their relevance for a diagnostic
test.
Studies are ongoing in our laboratory to follow these potential
biomarkers along with KRAS/BRAF SNP detection in regards to
the personalized anti-EGFR therapy for metastatic CRC [31].
This investigation might also be crucial to better understand
ctDNA release mechanisms. In addition, this study should be also
carried out in other cancer types or in various physiological or
pathological conditions that result or lead to ample release of cell-
free DNA.
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